PLx Pharma Executives
PLXPDelisted Stock | USD 0 0.00 0.00% |
PLx Pharma employs about 16 people. The company is managed by 20 executives with a total tenure of roughly 95 years, averaging almost 4.0 years of service per executive, having 0.8 employees per reported executive. Discussion of PLx Pharma's management performance can provide insight into the enterprise performance.
David Luci CEO President CEO, Secretary, Director |
Michael Valentino Chairman Ex Chairman |
PLx |
PLx Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.6439) % which means that it has lost $0.6439 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7518) %, meaning that it created substantial loss on money invested by shareholders. PLx Pharma's management efficiency ratios could be used to measure how well PLx Pharma manages its routine affairs as well as how well it operates its assets and liabilities.PLx Pharma Workforce Comparison
PLx Pharma is considered to be number one stock in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 25,191. PLx Pharma adds roughly 16.0 in number of employees claiming only tiny portion of equities under Health Care industry.
PLx Pharma Notable Stakeholders
A PLx Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as PLx Pharma often face trade-offs trying to please all of them. PLx Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting PLx Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Luci | President CEO, Secretary, Director | Profile | |
Michael Valentino | Ex Chairman | Profile | |
Steven Valentino | Vice President - Trade Sales | Profile | |
Tom Long | Vice President - Manufacturing & Technical Operations | Profile | |
Rita OConnor | CFO | Profile | |
Rita Connor | CFO | Profile | |
Natasha Giordano | Director | Profile | |
Robert Casale | Director | Profile | |
Kirk Calhoun | Director | Profile | |
Gary Balkema | Director | Profile | |
John Hadden | Director | Profile | |
Tony Bartsh | Director | Profile | |
CPA CPA | CFO Chain | Profile | |
CFA CFA | Member Group | Profile | |
Janet Barth | VP Communications | Profile | |
Robert Shawah | Chief Accounting Officer, Treasurer | Profile | |
Joanne Cotignola | VP Marketing | Profile | |
MBA MBA | Member Group | Profile | |
Ronald Zimmerman | Founder Advisor | Profile | |
Patrick Lonergan | Member Group | Profile |
About PLx Pharma Management Performance
The success or failure of an entity such as PLx Pharma often depends on how effective the management is. PLx Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of PLx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the PLx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. PLx Pharma Inc. was incorporated in 2002 and is headquartered in Sparta, New Jersey. Plx Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
The data published in PLx Pharma's official financial statements usually reflect PLx Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of PLx Pharma. For example, before you start analyzing numbers published by PLx accountants, it's critical to develop an understanding of what PLx Pharma's liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of PLx Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, PLx Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in PLx Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of PLx Pharma. Please utilize our Beneish M Score to check the likelihood of PLx Pharma's management manipulating its earnings.
PLx Pharma Workforce Analysis
Traditionally, organizations such as PLx Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare PLx Pharma within its industry.PLx Pharma Manpower Efficiency
Return on PLx Pharma Manpower
Revenue Per Employee | 513K | |
Revenue Per Executive | 410.4K | |
Net Loss Per Employee | 2.9M | |
Net Loss Per Executive | 2.3M | |
Working Capital Per Employee | 3.8M | |
Working Capital Per Executive | 3.1M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in PLx Stock
If you are still planning to invest in PLx Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PLx Pharma's history and understand the potential risks before investing.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |